Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week High – Should You Buy?
04:49am, Thursday, 02'nd Apr 2026
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $40.43 and last traded at $40.41, with a volume o
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
04:07pm, Wednesday, 01'st Apr 2026
NEW YORK, April 1, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio
11:11am, Wednesday, 01'st Apr 2026
BIIB's $5.6B offer to acquire APLS is set to add two key immunology drugs, boosting near-term revenues and strengthening its push into high-growth rare disease markets.
Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?
08:55am, Wednesday, 01'st Apr 2026
Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in th
Pre-Market Stock Futures: Futures are trading higher after an explosive rally on Tuesday, sparked by the President's comments that he wants to end the war soon. While this is hardly the final straw fo
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of A
Biogen Agrees $5.6B Apellis Deal as Shares Surge 136% on Announcement
04:11pm, Tuesday, 31'st Mar 2026
Biogen (BIIB) is moving decisively to reposition its growth profile, agreeing to acquire Apellis Pharmaceuticals (APLS) for $5.6 billion in a deal that could pr
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio
12:22pm, Tuesday, 31'st Mar 2026
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6 billion, it was announced on Tuesday. Apel
MILWAUKEE, March 31, 2026 /PRNewswire/ -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction wi
Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?
11:38am, Tuesday, 31'st Mar 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Why This Pharma Stock More Than Doubled Today
09:41am, Tuesday, 31'st Mar 2026
A small biopharmaceutical firm was getting a big boost Tuesday after Biogen agreed to buy it for $5.6 billion.
Wall Street Rallies on Latest U.S.-Iran Developments
09:07am, Tuesday, 31'st Mar 2026
Stock futures are indicating another strong open, buoyed by the latest upbeat Iran developments
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio
08:20am, Tuesday, 31'st Mar 2026
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) to Biogen Inc. for $41.00 per share in cash and a no
Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion
07:44am, Tuesday, 31'st Mar 2026
Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expanding its portfolio in immunology and rare-disease medicines.
